title: Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT.
abstract: Among the immunocompetent, infections with parvovirus B19 (B19V) and human bocavirus (HBoV) 1 range clinically from asymptomatic to severe, while following allogeneic hematopoietic SCT (HSCT) B19V can cause a persistent severe illness. The epidemiology and clinical impact of HBoV1 and the other emerging parvovirus 4 (PARV4) among immunocompromised patients have not been established. To determine the occurrence and clinical spectrum of B19V, PARV4 and HBoV1 infections, we performed a longitudinal molecular surveillance among 53 allogeneic HSCT recipients for pre- and post-HSCT DNAemias of these parvoviruses. Quantitative real-time PCR showed B19V DNA in sera of 16 (30%) patients, at mean levels of 4.6 × 10(3), 9.9 × 10(7), 1.1 × 10(10) and 1.6 × 10(2) B19V DNA copies/mL pre-HSCT (9/53), and at 1 (6/53), 2 (4/53) and 3 months (1/25) post HSCT, respectively. However, no clinical manifestation correlated with the presence of B19V viremia. All B19V sequences were of genotype 1. None of the sera investigated contained PARV4 or HBoV1 DNAs. Our data demonstrate B19V viremia to be frequent among pediatric allogeneic HSCT recipients, yet without apparent clinical correlates. PARV4 or HBoV1 viremias were not seen in these immunocompromised patients.
authors.affiliation: 1] Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland [2] Department of Pediatrics, Porvoo Hospital, Porvoo, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Rahiala
authors.forename: M
authors.initials: M
authors.lastname: Koskenvuo
authors.forename: P
authors.initials: P
authors.lastname: Norja
authors.forename: M
authors.initials: M
authors.lastname: Meriluoto
authors.forename: M
authors.initials: M
authors.lastname: Toppinen
authors.forename: A
authors.initials: A
authors.lastname: Lahtinen
authors.forename: E
authors.initials: E
authors.lastname: Väisänen
authors.forename: M
authors.initials: M
authors.lastname: Waris
authors.forename: T
authors.initials: T
authors.lastname: Vuorinen
authors.forename: U
authors.initials: U
authors.lastname: Saarinen-Pihkala
authors.forename: M
authors.initials: M
authors.lastname: Lappalainen
authors.forename: T
authors.initials: T
authors.lastname: Allander
authors.forename: O
authors.initials: O
authors.lastname: Ruuskanen
authors.forename: K
authors.initials: K
authors.lastname: Hedman
authors.forename: M
authors.initials: M
authors.lastname: Söderlund-Venermo
authors.forename: K
authors.initials: K
authors.lastname: Vettenranta
mesh_terms: D000293:Adolescent; D052660:Bocavirus / Q000302:isolation & purification*; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010322:Parvoviridae Infections / Q000097:blood* / Q000235:genetics; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous